Treatment of Chronic Cough
For chronic cough, first identify and treat the underlying cause through a systematic protocol-based approach, then use multimodality speech pathology therapy and/or gabapentin for unexplained or refractory cases.
Initial Diagnostic and Treatment Approach
The treatment of chronic cough (defined as cough persisting >8 weeks) requires a structured algorithmic approach rather than shotgun empiric therapy 1.
Step 1: Protocol-Based Assessment
- Perform objective testing for bronchial hyperresponsiveness and eosinophilic bronchitis (sputum eosinophils, exhaled nitric oxide), or conduct a therapeutic corticosteroid trial 1
- Obtain chest radiography and spirometry as baseline cost-effective tests 2
- Assess for medication triggers, particularly ACE inhibitors (discontinue if present) 2
Step 2: Treat Common Causes
The five most common etiologies to address empirically are:
- Upper airway cough syndrome (postnasal drip)
- Asthma/cough variant asthma
- Nonasthmatic eosinophilic bronchitis
- Gastroesophageal reflux disease (GERD)
- Laryngopharyngeal reflux 2, 3
Critical caveat: For GERD-related cough, treatment should be initiated based on clinical profile rather than waiting for testing 4. However, if the patient lacks features of gastroesophageal acid reflux on workup, do not prescribe proton pump inhibitors as they are ineffective in this scenario 1.
Step 3: Optimize Treatment Trials
Allow 4-6 weeks of empiric treatment for suspected causes before declaring treatment failure 3. Ensure patient adherence before concluding a trial has failed 1.
Management of Unexplained/Refractory Chronic Cough
When cough persists despite systematic investigation and appropriate treatment trials, it becomes unexplained chronic cough (UCC), affecting 5-10% of patients seeking care for chronic cough 1.
First-Line Treatment for UCC
Multimodality speech pathology therapy is the primary recommended intervention 1. This cough control therapy includes:
- Education about cough hypersensitivity
- Techniques to anticipate and control the urge to cough
- Strategies to reduce laryngeal irritation
- Psychoeducational counseling 5
This approach targets the underlying mechanism of vagal afferent hypersensitivity and cough hypersensitivity syndrome 6, 7.
Pharmacologic Neuromodulation
Gabapentin is recommended as a therapeutic trial when speech pathology is insufficient or unavailable 1.
Dosing protocol:
- Start at 300 mg once daily
- Escalate by adding additional doses each day as tolerated
- Maximum dose: 1,800 mg daily in two divided doses 1
Important requirements:
- Discuss potential side effects and risk-benefit profile before initiation
- Reassess risk-benefit at 6 months before continuing 1
- The quality of life improvements outweigh side effects in appropriately selected patients 1
Alternative neuromodulators include low-dose morphine (preferred by some experts), pregabalin, or amitriptyline for refractory cases 3, 7.
What NOT to Do in UCC
Avoid inhaled corticosteroids if tests for bronchial hyperresponsiveness and eosinophilia (sputum eosinophils, exhaled nitric oxide) are negative 1. When intervention fidelity is properly addressed, ICS are ineffective for true UCC 1.
Avoid proton pump inhibitors if the workup for acid gastroesophageal reflux disease is negative 1.
Common Pitfalls
- Incomplete investigation: Declaring cough "unexplained" before completing systematic evaluation and adequate treatment trials of common causes
- Inadequate treatment intensity: Assuming GERD is ruled out when empiric therapy fails—the therapy may simply not have been intensive enough 4
- Premature testing: Ordering extensive diagnostic tests before trying empiric treatment for the most likely diagnoses 2, 3
- Ignoring adherence: Not verifying patient adherence before concluding treatment failure 1
Emerging Therapies
P2X3 receptor antagonists (gefapixant, recently licensed in EU/UK/Japan) represent promising future options for refractory chronic cough by blocking neuronal excitability 6, 7, though they are not yet widely available.